Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5JJ83)

Drug Name
Varespladib Drug Info
Synonyms
Varespladib; 172732-68-2; LY315920; Varespladib (LY315920); LY-315920; S-5920; VAREPLADIB; 2Q3P98DATH; ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl}oxy)acetic acid; 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid; CHEMBL148674; S 5920; 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid; 2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yloxy)acetic acid; SMR004701444; Varespladib [INN]; Varespladib [USAN]; Varespladib [USAN:INN]; UNII-2Q3P98DATH; varespladibum; ((3-(AMINO(OXO)ACETYL)-1-BENZYL-2-ETHYL-1H-INDOL-4-YL)OXY)ACETIC ACID; VRD; VARESPLADIB [MI]; Varespladib (USAN/INN); SCHEMBL26726; VARESPLADIB [WHO-DD]; MLS006010414; MLS006010980; varespladib methyl (A-002); varespladib sodium (A-001); LY 315920 (Varespladib); GTPL9657; DTXSID50169378; EX-A153; CHEBI:189668; BCPP000175; HMS3654E04; HMS3744O03; AMY19698; BCP01854; BDBM50055366; MFCD00944812; s1110; ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetate; AKOS015842901; compound 6m [PMID: 8978844]; BCP9000883; CCG-268404; DB11909; EX-8676; SB16690; NCGC00346491-01; NCGC00346491-02; NCGC00346491-08; NCGC00346491-12; AC-32931; AS-16956; HY-13402; A-001; FT-0659937; SW219559-1; A25228; D08107; EN300-144829; J-010846; Q7915613; BRD-K09711437-001-01-9; Z1721255146; (3-Aminooxalyl-1-benzyl-2-ethyl-1H-indol-4-yloxy)-acetic acid; 2-[2-ethyl-3-oxamoyl-1-(phenylmethyl)indol-4-yl]oxyethanoic acid; ((3-(Aminooxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; (3-Aminooxalyl-1-benzyl-2-ethyl-2,3-dihydro-1H-indol-4-yloxy)-acetic acid; 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetic acid; ACETIC ACID, ((3-(AMINOOXOACETYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL)OXY)-; Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-,; LY 315920; Varespladib; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic aci
Cross-matching ID
PubChem CID
155815
ChEBI ID
CHEMBL148674
TTD Drug ID
D74PRE

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Nucleotide excision repair 2.12 0.00e+0 40/47 (85.11%) RAD23B;RFC5;GTF2H4;...
Linoleic acid metabolism -1.77 4.63e-2 21/29 (72.41%) CYP3A4;CYP2E1;PLA2G4A;...
IL-17 signaling pathway -1.81 4.30e-2 84/94 (89.36%) CCL2;IL17RB;IFNG;...
Cytokine-cytokine receptor interaction -2.03 0.00e+0 246/295 (83.39%) CCL1;CCR6;CCL2;...
Viral protein interaction with cytokine and cytokine re... -2.37 0.00e+0 84/100 (84%) IL22RA1;PPBP;CCL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H